Temedica Collaboration with BMS for Psoriasis Digital Companion

Temedica GmbH announced it is developing a digital companion for patients with psoriasis for BMS. The app’s purpose is to support patients and help them manage their disease better and includes advice from both patients and healthcare professionals. Psoriasis affects approximately 2 million people in Germany and is one of the most common chronic inflammatory skin diseases. Dr. Michael May, Medical Director at Bristol Myers Squibb in Germany commented that the goal of providing digital health services is to make a positive impact on the lives of patients living with serious disease, making their experience as patients feel more supported. The digital campaign will provide psoriasis patients a better understanding on their disease by recommending behavioral changes to improve their health. Their health information may also be shared with their healthcare providers, who can monitor their patient’s health and adjust therapy as needed.

Read more about this news release here.